

Samumed Selected for Seven Presentations in Five Therapeutic Areas at American College of Rheumatology 2016 Annual Meeting

Company's Wnt Regulation Platform Shows Promise across Multiple Disease States

San Diego, CA—November 1, 2016 – Samumed, a leader in tissue regeneration, today announced it has been selected to feature seven presentations in five different therapeutic areas at the 2016 American College of Rheumatology (ACR) Annual Meeting from November 11–16 in Washington, D.C.

The ACR Annual Meeting is the premier educational event for physicians, health professionals and scientists who treat those with or at risk for arthritis, rheumatic and musculoskeletal diseases. Samumed's presentations will focus on the application of the company's novel, small-molecule Wnt pathway inhibitor compounds to treat the underlying pathology leading to the symptoms rather than the symptoms alone of the following diseases: Chronic Tendinopathy, Degenerative Disc Disease, Scleroderma, Osteoarthritis and Psoriasis.

"Samumed's unique understanding of the cell process and how to modulate it enables us to develop drugs that actually recover and restore the health of diseased tissues as opposed to simply providing symptom relief," said Yusuf Yazici, M.D., Chief Medical Officer of Samumed. "We are excited to return to the ACR Annual Meeting with seven presentations that highlight the progress we've made in five disease areas with two of our small-molecule compounds, SM04755 and SM04690."

Samumed's technology platform is based on the company's ability to modulate a cell process known as the Wnt pathway—which regulates the self-renewal and differentiation of adult stem cells and has been implicated in hundreds of diseases, primarily in oncology and various degenerative conditions. The company currently has seven clinical-stage programs in development.

In addition to progress in rheumatology, Samumed has also made progress recently in other areas. Researchers recently completed a successful Phase I trial in Pulmonary Fibrosis and will be launching the next phase trial this year. The company expects to report results from an Androgenic Alopecia trial at a medical conference in spring 2017.

Samumed CEO Osman Kibar recently spoke about the full breadth of the company's research efforts in a presentation to the Royal Society of Medicine in London, which can be viewed at <https://videos.rsm.ac.uk/video/regenerative-medicine-platform-initiative>.

Abstracts about Samumed's seven ACR presentations are available online at the [ACR Meeting Abstract webpage](#). Below is the full list of the Samumed presentations at ACR and information about the diseases:

PRESENTATION INFORMATION

Title: [Discovery of a Small Molecule Inhibitor of the Wnt Pathway \(SM04755\) As a Potential Topical Treatment for Chronic Tendinopathy](#)

Date: November 14, 2016

Abstract number: 1104

Title: [Discovery of a Small Molecule Inhibitor of the Wnt Pathway \(SM04755\) As a Potential Topical Treatment for Scleroderma](#)

Date: November 14, 2016

Abstract number: 1856

Title: [Discovery of a Small Molecule Inhibitor of the Wnt Pathway \(SM04690\) As a Potential Treatment for Degenerative Disc Disease](#)

Date: November 15, 2016

Abstract number: 2120

Title: [A Small Molecule, SM04690, Has Inhibitory Effects on the Wnt Pathway and Inflammation in Vitro, with Potential Implications for the Treatment of Osteoarthritis](#)

Date: November 15, 2016

Abstract number: 2143

Title: [Radiographic Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor \(SM04690\) in the Treatment of Osteoarthritis of the Knee](#)

Date: November 15, 2016

Abstract number: 2350

Title: [Analysis of Pain and Function Components in Omeract-Oarsi Strict Responders from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor \(SM04690\) in the Treatment of Osteoarthritis of the Knee](#)

Date: November 15, 2016

Abstract number: 2368

Title: [Discovery of a Small Molecule Inhibitor of the Wnt Pathway \(SM04755\) As a Potential Topical Treatment for Psoriasis](#)

Date: November 15, 2016

Abstract number: 2704

DISEASE INFORMATION

ABOUT CHRONIC TENDINOPATHY

Chronic Tendinopathy is an inflammatory and degenerative condition caused by injuries or overuse.

ABOUT SCLERODERMA

Scleroderma is an autoimmune fibrotic disease, which presents skin manifestations among others.

ABOUT DEGENERATIVE DISC DISEASE

Degenerative Disc Disease (DDD), one of the main causes of low back pain, is characterized by degeneration of intervertebral disc, nucleus pulposus and cartilage matrix, resulting in decreased disc height and function.

ABOUT OSTEOARTHRITIS

Osteoarthritis (OA) involves thinning cartilage and increased subchondral bone. Amongst many cellular processes, inflammation has been associated with OA.

ABOUT PSORIASIS

Psoriasis is an autoimmune disease of the skin, characterized by inflammation and fibrosis, producing patches of red, itchy and scaly skin.

###

ABOUT SAMUMED, LLC

Based in San Diego, CA, Samumed (www.samumed.com) is a pharmaceutical platform company focused on advancing regenerative medicine and oncology applications through research and innovation.

Samumed has discovered new targets and biological processes in the Wnt pathway, allowing the team to develop small molecule drugs that potentially address numerous degenerative conditions as well as many forms of cancer.